International Consortium of Investigative Journalists

Following the paper trail to Guatemala to uncover what records can’t reveal about access to Keytruda

I had read countless legal documents about the world's bestselling drug. But it took a trip to Latin America to see how ...
Fierce Biotech

Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data

Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the ...
MarketBeat on MSN

Inhibrx Biosciences' INBRX-106 combo tops KEYTRUDA alone in phase 2 cancer study

Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck's KEYTRUDA ...
Hosted on MSN

Merck partners with Erasca to test new Keytruda combo

New cancer trial: Merck and Erasca will test ERAS-0015 with Keytruda in RAS-mutant solid tumors under the AURORAS-1 study. Potential treatment boost: The combination targets tumor pathways and immune ...
Healthline

Imfinzi vs. Keytruda: What You Should Know

Imfinzi (durvalumab) and Keytruda (pembrolizumab) are prescription drugs used to treat various forms of cancer. Both drugs are administered as intravenous (IV) infusion into a vein. Your dosage for ...
Nasdaq

Data from Exploratory Analysis Show Merck’s KEYTRUDA® (pembrolizumab) Improved Overall Survival as Monotherapy for the First-Line Treatment of Metastatic Non-Small Cell Lung ...

New Findings from Phase 3 KEYNOTE-042 Study Were Presented Today at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2019 “KRAS mutations occur in approximately 20% of people ...
Becker's Hospital Review

Mounjaro surpasses Keytruda as top-selling drug

Mounjaro surpasses Keytruda top sales with $8.7B in Q1 2025, marking a 125% increase for Eli Lilly over Merck's cancer drug.
FiercePharma

Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted ...
FiercePharma

Merck's KEYTRUDA® (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the pivotal KEYNOTE-010 study, the first study of its kind to ...